Drug-resistant cancer models are essential tools for evaluating novel therapeutics that overcome resistance to standard-of-care treatments. These models are developed by chronically exposing cancer cell lines or patient-derived xenografts (PDXs) to chemotherapeutic agents, targeted therapies, or immunotherapies until they acquire resistance traits reflective of clinical relapse or refractory disease.

We offer a wide range of drug testing using preclinical drug-resistant tumor models below.